Myeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:

Similar documents
Heme 9 Myeloid neoplasms

HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS

Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms

Myelodysplastic Syndromes Myeloproliferative Disorders

Pathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16

Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED

Hematology Unit Lab 2 Review Material

WBCs Disorders 1. Dr. Nabila Hamdi MD, PhD

Chronic Idiopathic Myelofibrosis (CIMF)

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Primary myelofibrosis

Polycthemia Vera (Rubra)

Disclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms

HEMATOLOGIC MALIGNANCIES BIOLOGY

Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Pathology of Hematopoietic and Lymphoid tissue

Polycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi

74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow

MYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).

Case Presentation No. 075

WHO Update to Myeloproliferative Neoplasms

بسم هللا الرحمن الرحيم

Pathology of Hematopoietic and Lymphoid tissue

WBCs Disorders. Dr. Nabila Hamdi MD, PhD

2013 Pathology Student

Myelodysplastic Syndromes: Everyday Challenges and Pitfalls

Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and

5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

Myelodysplastic Syndrome: Let s build a definition

MYELOPROLIFERATIVE DISEASE. Dr Mere Kende MBBS (UPNG), MMED (Path),MAACB, MACTM, MACRRM (Aus) Lecturer-SMHS UPNG

MDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?

WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities

Juvenile Myelomonocytic Leukemia (JMML)

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information

WHO Classification 7/2/2009

2 nd step do Bone Marrow Study If possible both the aspiration and

MYELODYSPLASTIC SYNDROMES

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University

Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ

JAK2 V617F analysis. Indication: monitoring of therapy

[COMPREHENSIVE GENETIC ASSAY PANEL ON

CHALLENGING CASES PRESENTATION

CHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009

Neoplastic proliferation arising from white blood cells. Introductory remarks. Classification

MPL W515L K mutation

Acute myeloid leukemia. M. Kaźmierczak 2016

Classification of Hematologic Malignancies. Patricia Aoun MD MPH

GENETICS OF HEMATOLOGICAL MALIGNANCIES

MDS: Who gets it and how is it diagnosed?

Disclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.

Bone marrow histopathology in Ph - CMPDs. - the new WHO classification - Juergen Thiele Cologne, Germany

Peripheral Blood Smear: Diagnostic Clues and Algorithms

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD

Chronic Myelomonocytic Leukemia with molecular abnormalities SH

Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328

Blood Cell Identification: 2011-B Mailing: Acute Myeloid Leukemia (AML)

CLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Kaaren Reichard Mayo Clinic Rochester

The Internists Approach to Polycythemia and Implications of Uncontrolled Disease

Approaching myeloid neoplasms: diagnostic algorithms

Hematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD

HAEMATOLOGICAL MALIGNANCY

MYELOPROLIFERATIVE NEOPLASMS

Molecular Hematopathology Leukemias I. January 14, 2005

Hematopathology Case Study

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

Disclosures/COI. Cases in Hematopathology. Outline. Heme Path Findings Not to Miss. Normal Peripheral Smear 6/30/2016

Laboratory Diagnosis for WBC Pathology

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:

Flow Cytometry. Bone Marrow Aspirate and Biopsy. Leukemia and Myelodysplastic Syndromes

MDS/MPN MPN MDS. Discolosures. Advances in the Diagnosis of Myeloproliferative Neoplasms. Myeloproliferative neoplasms

MPDs. Myeloproliferative Disorders OBJECTIVES MYELOPROLIFERATIVE NEOPLASMS

John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine St Louis, Missouri

Case Workshop of Society for Hematopathology and European Association for Haematopathology

If unqualified, Complete remission is considered to be Haematological complete remission

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...

MS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

If unqualified, Complete remission is considered to be Haematological complete remission

Conditions that mimic neoplasia in the bone marrow. Kaaren K. Reichard Mayo Clinic Rochester

Myeloproliferative Neoplasms and Treatment Overview

SH A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL

MPDs. Myeloproliferative Disorders OBJECTIVES MYELOPROLIFERATIVE NEOPLASMS

20/20 PATHOLOGY REPORTS

Faculty of Medicine Dr. Tariq Aladily

MS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD

Myeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination

SESSION 1 Reactive cytopenia and dysplasia

Ordering Physician CLIENT,CLIENT. Collected REVISED REPORT

London Cancer. Myelofibrosis guidelines. August Review August Version v1.0. Page 1 of 12

Acute Lymphoblastic and Myeloid Leukemia

Case #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed

Tim R. Randolph. PhD, MT(ASCP) Chair and Associate Professor Department of Biomedical Laboratory Science Saint Louis University

Flow Cytometry. Leukemia and Myelodysplastic Syndromes. Bone Marrow Aspirate and Biopsy

Transcription:

Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid differentiation) Acute : arrest in early stages Leukemia :neoplastic cell in the peripheral blood Age of presentation is around 50 can happen at any age "6months to 70 y " Stigmata of pancytopenia "the bone marrow Is replaced completely by neoplastic blasts" Splenomegaly Rarely as discrete mases Called myeloid sarcoma(rare disease around the mouth) We don t call it lymphoma?? Because it is not a lymphocytic tumor Diagnosis depends on: Morphology Immuneophenotype Karyotype (Predictive of prognosis)

Pathogenesis Mutations that result in arresting myeloid cells at an early stage of differentiation "inability to differentiate " A lot of mutations but please know this example is acute promyelocytic leukemia t(15;17) resulting in fusion of RARA with PML (The resulting fusion gene arrests myeloid cells at the promyelocyte stage) the good thing about the fusion gene is that we can design a drugs that target these genes one example is Treatment with all-trans retinoic acid (ATRA, a vitamin A derivative) which overcomes this protein and forces the cells to differentiate into neutrophils and the remission happen in one week, CURE RATE IS HIGH. DIC is a possible complication of APL. Morphology At least 20% blasts by definition (you need 20% blasts to call a tumor acute leukemia) Auer rods "needle shape structure in the cytoplasm"(it is purple in color or magenta color or deep pink color) In this figure we can see the the stage of differentiation The blast has a dominant white nucleolus AML: in the blast or promyelocyte In MPN and MDS: maturation and differentiation happen Auer rods are present in myeloblasts, indicating that the tumor is acute myeloid leukemia and not lymphoid, however, its absence does not rule acute myeloid leukemia out. In other words, they are specific for AML but not sensitive.

From the above table you have to know: The general classification "main classes " Note :the 3rd class (we can diagnose it without tests) previous exposure to =chemo thereby The cytogenetic translocation carries the best prognosis Immunophenotype CD34 "marker of stem cell or blasts, myeloid or lymphoid Myeloid markers MPO, CD33, CD13, CD117, CD15 MPO is the most specific There is an example of test can't find it in the sides "sorry"

Clinical manifestations Very similar to ALL (huge overlap), don t depend on the age DON T Stigmata of pancytopenia CNS manifestations are less frequent than ALL Treatment with chemotherapy and possibly SCT (stem cell transplantation) Prognosis is variable but oveall 5-year survival is~15-30%. (Bad prognosis) 2. MDS (Myelodysplastic syndrome): The term myelodysplasticsyndrome(mds) refers to a group of clonal stem cell disorders characterized by maturation defects that are associated with ineffective hematopoiesis with cytopenias and a high risk of transformation to AML (no cytosis the cells stay in the bone marrow ) Most cases are idiopathic (Some cases are induced by exposure to alkylating agents or ionizing radiation) - Can progress in to AML Pathogenesis involves genetic and epigenetic(change in the gene and not changing the sequence ) mutations that result in inability of the stem cells to have effective poeisis. Still able to proliferate and differentiate but in a disorderly manner! Morphology Hypercellular bone marrow Dysplastic changes Erythroid: Abnormal nuclear contour and iron deposits (ring sideroblasts) Myeloid: abnormal segmentation and granulation Megakaryocyte: small and monolobed

Clinical manifestations Age 50-70 Cytopenia and its effects (if there is a cytosis it is defiantly not MDS) Does not have to be PANcytopenia Patients may present with only anemia or only thrombocytopenia or only leukopenia transforms to AML in 10-40% of the cases Survival between 9-29 months 3. MPN (Myeloproliferative Neoplasms) Four major neoplasms Chronic myelogenous leukemia Polycythemia vera( discussed earlier ) Essential thrombocythemia Primary myelofibrosis Pathogeneses : The common pathogenic feature of myeloproliferative neoplasms is the presence of mutated, constitutively activated tyrosine kinases or other acquired aberrations in signaling pathways that lead to growth factor independence (uncontrolled growth). Still have the ability to differentiate These neoplasms have two fates: Spent phase: fibrosis (extensive) Blast phase: acute leukemia Ok let's start:

CML (chronic myelogenous leukaemia) The only neoplasm in which the molecular test is mandatory for diagnosis (BCR- ABL) Pathogenesis BCR-ABL translocation t(9;22) The same as in B-ALL Present in all cells (B, T, myeloid) It is a tyrosine kinase that results in uncontrolled proliferation Does NOT inhibit differentiation Disease course is marked by excessive production of relatively normal blood cells, particularly granulocytes(basophils) and platelets. Morphology Hypercellular bone marrow Splenomegaly with extensive extramedullary hematopoiesis High WBC count, often exceeding 100000 (may cause thrombosis) Clinical manifestations o Age 50-70 o Nonspecific symptoms of fatigue, weakness o Dragging sensation in the abdomen due to splenomegaly o Must be distinguished from leukemoid reaction o High WBC count secondary to infection or infarction o Best done by molecular testing for BCR-ABL o Slowly progressive disease (Median survival is 3 years without treatment) o Can progress to accelerated phase(anemia, thrombocytopenia and additional genetic mutations)

o Progress to blast phase(70% AML 30% ALL) Myeloid in to lymphoid?!!!!!! how? Remember that the mutation is at the stem cell level o Rarely progresses to spent phase with fibrosis Primary myelofibrosis The hallmark of primary myelofibrosis is : - development of obliterative marrow fibrosis, which reduces bone marrow hematopoiesis and leads to cytopenias - extensive extramedullary hematopoiesis pathogenesis JAK2 mutation in ~50-60% of the cases Neoplastic cells involve the megakaryocytes (always there is fibrosis) Secrete fibrogenic factors resulting in extensive fibrosis PDGF and TGF-B Extramedullary hematopoiesis with marked splenomegaly (may reach 4 KG and can could be felt on the right side) Morphology Peripheral blood: leukoerythroblastosis same as myelophthisic anemia Tear drop RBCs Erythroid precursor cells Immature myeloid cells As you recall this is also found in myelophthisic anemia Abnormally large platelets Bone marrow: Severe fibrosis Abnormally large and clustered megakaryocytes

Clinical manifestations Age more than 60 Anemia and splenomegaly Fatigue, weakness and night sweats Lab results Anemia: normochromic and normocytic Leukoerythroblatosis Bone marrow is a must for diagnosis (hypercellularity,fibrosis, cluster of megakaryocytes) Median survival is 4-5 years 5-20% transform to AML Treat with JAK2 inhibitors and possibly SCT Answers to the Qs: 1-20% 2- AML with recurrent cytogenetic abnormality 3- thrombocytosis 4-CML 5-PMF